HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Requiring institutions to inform participants who have completed therapy on SWOG-8892 (RT +/- cisplatin for nasopharyngeal cancer) about early study closure: right idea, wrong patients.

AuthorsR J Amdur, E Bankert
JournalInternational journal of radiation oncology, biology, physics (Int J Radiat Oncol Biol Phys) Vol. 38 Issue 3 Pg. 673 (Jun 01 1997) ISSN: 0360-3016 [Print] United States
PMID9231694 (Publication Type: Letter)
Chemical References
  • Antineoplastic Agents
  • Radiation-Sensitizing Agents
  • Cisplatin
Topics
  • Antineoplastic Agents (therapeutic use)
  • Carcinoma, Squamous Cell (drug therapy, radiotherapy, therapy)
  • Cisplatin (therapeutic use)
  • Clinical Trials, Phase III as Topic (legislation & jurisprudence, standards)
  • Combined Modality Therapy
  • Humans
  • Multicenter Studies as Topic (legislation & jurisprudence, standards)
  • Nasopharyngeal Neoplasms (drug therapy, radiotherapy, therapy)
  • Patient Compliance
  • Professional Staff Committees (legislation & jurisprudence, standards)
  • Radiation-Sensitizing Agents (therapeutic use)
  • Truth Disclosure
  • United States

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: